VTRS Earnings Date: Nov 5, 2026 (Estimated) — Viatris Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is VTRS's next earnings date?
Viatris Inc. (VTRS) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.64 on revenue of $3.79B.
How did VTRS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Viatris Inc. posted EPS of $0.69 versus the $0.60 estimate, a beat of 13.1%. Revenue was $3.76B against a $3.68B estimate. The stock's 1-day post-earnings move was -7.7%.
How much does VTRS stock move after earnings?
VTRS beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.6% (up or down) in the day after earnings.
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.60 | 0.69 | +13.11% | $3.76B | ✅ Beat | -7.71% | -8.79% | -3.31% |
| 2026-05-07 | Q1 2026 | 0.51 | 0.59 | +15.69% | $3.51B | ✅ Beat | +8.97% | +8.91% | +0.25% |
| 2026-02-26 | Q4 2025 | 0.53 | 0.57 | +7.55% | $3.69B | ✅ Beat | -5.16% | -8.53% | -16.17% |
| 2025-11-06 | Q3 2025 | 0.62 | 0.67 | +8.06% | $3.76B | ✅ Beat | -5.93% | +2.41% | +2.89% |
| 2025-08-07 | Q2 2025 | 0.56 | 0.62 | +10.71% | $3.58B | ✅ Beat | +7.31% | +18.97% | +21.35% |
| 2025-02-27 | Q4 2024 | 0.57 | 0.54 | -5.26% | $3.52B | ❌ Miss | -15.22% | -15.66% | -20.36% |
| 2024-11-07 | Q3 2024 | 0.68 | 0.75 | +10.29% | $3.75B | ✅ Beat | +13.46% | +11.96% | +10.56% |
| 2024-05-09 | Q1 2024 | 0.67 | 0.67 | +0.00% | $3.66B | ➖ Inline | -4.98% | -6.26% | -10.36% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $3.75B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Brands | 64.6% | $2.42B | +5.9% | $4.53B | $2.12B | $2.28B | $2.44B |
| Generics | 35.4% | $1.33B | +3.3% | $2.77B | $1.13B | $1.28B | $1.31B |
By region
Q2 FY26 · $3.76B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Developed Markets | 58.6% | $2.20B | +3.4% | $2.18B | $1.90B | $2.13B | $2.27B |
| Greater China | 19.0% | $713.8M | +21.2% | $523.1M | $555.5M | $588.9M | $615.2M |
| Emerging Markets | 14.5% | $543.8M | -2.4% | $522.7M | $523.1M | $556.9M | $571.8M |
| Japan, Australia and New Zealand | 7.9% | $296.2M | -3.4% | $338.0M | $277.1M | $306.7M | $307.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.